Alfred Schinkel

Group leader

For specifics on my CV, please see also under “Work Experience”.

Starting in 1997, my group has been studying genes and proteins that affect drug resistance in tumors, or influence the pharmacological and toxicological behavior of (anticancer) drugs and toxins, including carcinogens. Of special interest are multispecific drug efflux and uptake transporters, as well as drug-metabolizing enzymes. Insight into these systems may: i) improve pharmacotherapy approaches for cancer and other diseases; ii) increase insights into factors determining susceptibility to toxins and carcinogens, and; iii) allow elucidation of physiological functions. To understand the roles of these proteins we often generate and analyze knockout or transgenic mice lacking or overexpressing the relevant genes.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.